Literature DB >> 17088255

Binding of elongation factor eEF1A2 to phosphatidylinositol 4-kinase beta stimulates lipid kinase activity and phosphatidylinositol 4-phosphate generation.

Sujeeve Jeganathan1, Jonathan M Lee.   

Abstract

Eukaryotic protein translation elongation factor 1 alpha 2 (eEF1A2) is an oncogene that transforms mammalian cell lines and increases their tumorigenicity in nude mice. Increased expression of eEF1A2 occurs during the development of breast, ovarian, and lung cancer. Here, we report that eEF1A2 directly binds to and activates phosphatidylinositol 4-kinase III beta (PI4KIIIbeta), an enzyme that converts phosphatidylinositol to phosphatidylinositol 4-phosphate. Purified recombinant eEF1A2 increases PI4KIIIbeta lipid kinase activity in vitro, and expression of eEF1A2 in rat and human cells is sufficient to increase overall cellular phosphatidylinositol 4-kinase activity and intracellular phosphatidylinositol 4-phosphate abundance. siRNA-mediated reduction in eEF1A2 expression concomitantly reduces phosphatidylinositol 4-kinase activity. This identifies a physical and functional relationship between eEF1A2 and PI4KIIIbeta.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17088255     DOI: 10.1074/jbc.M602955200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  9 in total

1.  eEF1A phosphorylation in the nucleus of insulin-stimulated C2C12 myoblasts: Ser⁵³ is a novel substrate for protein kinase C βI.

Authors:  Manuela Piazzi; Alberto Bavelloni; Irene Faenza; William Blalock; Andrea Urbani; Simona D'Aguanno; Roberta Fiume; Giulia Ramazzotti; Nadir Mario Maraldi; Lucio Cocco
Journal:  Mol Cell Proteomics       Date:  2010-10-05       Impact factor: 5.911

2.  Structural rationale for the cross-resistance of tumor cells bearing the A399V variant of elongation factor eEF1A1 to the structurally unrelated didemnin B, ternatin, nannocystin A and ansatrienin B.

Authors:  Pedro A Sánchez-Murcia; Álvaro Cortés-Cabrera; Federico Gago
Journal:  J Comput Aided Mol Des       Date:  2017-09-12       Impact factor: 3.686

3.  Eef1a2 promotes cell growth, inhibits apoptosis and activates JAK/STAT and AKT signaling in mouse plasmacytomas.

Authors:  Zhaoyang Li; Chen-Feng Qi; Dong-Mi Shin; Adriana Zingone; Helen J Newbery; Alexander L Kovalchuk; Catherine M Abbott; Herbert C Morse
Journal:  PLoS One       Date:  2010-05-21       Impact factor: 3.240

4.  Robust patterns in the stochastic organization of filopodia.

Authors:  Asma N Husainy; Anne A Morrow; Theodore J Perkins; Jonathan M Lee
Journal:  BMC Cell Biol       Date:  2010-11-17       Impact factor: 4.241

5.  Eukaryotic elongation factor 1A2 cooperates with phosphatidylinositol-4 kinase III beta to stimulate production of filopodia through increased phosphatidylinositol-4,5 bisphosphate generation.

Authors:  Sujeeve Jeganathan; Anne Morrow; Anahita Amiri; Jonathan M Lee
Journal:  Mol Cell Biol       Date:  2008-05-12       Impact factor: 4.272

6.  Eukaryotic elongation factor 1A interacts with sphingosine kinase and directly enhances its catalytic activity.

Authors:  Tamara M Leclercq; Paul A B Moretti; Mathew A Vadas; Stuart M Pitson
Journal:  J Biol Chem       Date:  2008-02-08       Impact factor: 5.157

Review 7.  The eEF1A Proteins: At the Crossroads of Oncogenesis, Apoptosis, and Viral Infections.

Authors:  Wasim Abbas; Amit Kumar; Georges Herbein
Journal:  Front Oncol       Date:  2015-04-07       Impact factor: 6.244

8.  Proto-oncogenic isoform A2 of eukaryotic translation elongation factor eEF1 is a target of miR-663 and miR-744.

Authors:  A Vislovukh; G Kratassiouk; E Porto; N Gralievska; C Beldiman; G Pinna; A El'skaya; A Harel-Bellan; B Negrutskii; I Groisman
Journal:  Br J Cancer       Date:  2013-05-21       Impact factor: 7.640

9.  Translation Elongation Factor eEF1A2 is a Novel Anticancer Target for the Marine Natural Product Plitidepsin.

Authors:  Alejandro Losada; María José Muñoz-Alonso; Carolina García; Pedro A Sánchez-Murcia; Juan Fernando Martínez-Leal; Juan Manuel Domínguez; M Pilar Lillo; Federico Gago; Carlos M Galmarini
Journal:  Sci Rep       Date:  2016-10-07       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.